NDAORALTABLETPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
22
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (2)
Clinical Trials (5)
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
Started Jun 2024
0NSCLC, Stage IIIALK-rearrangement
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Started Jan 2024
154 enrolled
Non-small Cell Lung Cancer (NSCLC)
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
Started Dec 2023
12 enrolled
Healthy Volunteers
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
Started May 2023
50 enrolled
Non-small Cell Lung Cancer (NSCLC)
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Started Aug 2022
65 enrolled
Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Loss of Exclusivity
LOE Date
Nov 10, 2035
117 months away
Patent Expiry
Nov 10, 2035
Exclusivity Expiry
May 22, 2027